A Medical Device Daily
Curon Medical (Fremont, California) and Novasys Medical (Newark, California) jointly reported that they entered an agreement for a worldwide, exclusive license of certain patents for which Novasys Medical is paying $650,000 in cash.
Novasys said it has secured the rights to use certain intellectual property of Curon for the treatment of urinary incontinence and other genito-urinary conditions in men and women.
Curon said the intellectual property (IP) involved is unrelated to its core business, and that this transaction will have no adverse impact on its applications of radio frequency energy for the treatment of gastroesophageal reflux disease (GERD) or bowel incontinence.
“With the recent successful launch of our Renessa system for the treatment of stress urinary incontinence in women, we are looking to future development opportunities as well,” said Debra Reisenthel, president and CEO of Novasys. “The IP we have licensed from Curon will assist us in expanding the potential applications for our core technology for the treatment of various genito-urinary conditions in both women and men.”
Curon develops products for the treatment of gastrointestinal disorders.
Novasys develops therapies in women's health. The company's initial focus is the development and commercialization of the Renessa system, a non-surgical approach to the treatment of female stress urinary incontinence.